These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A model for the future conduct of pharmacovigilance. Waller PC; Evans SJ Pharmacoepidemiol Drug Saf; 2003; 12(1):17-29. PubMed ID: 12616844 [TBL] [Abstract][Full Text] [Related]
4. Pharmacovigilance in India: how safe are the new drugs? How sure are we? Joshi SR; Sapatnekar SM J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970 [No Abstract] [Full Text] [Related]
5. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vellozzi C; Broder KR; Haber P; Guh A; Nguyen M; Cano M; Lewis P; McNeil MM; Bryant M; Singleton J; Martin D; DeStefano F Vaccine; 2010 Oct; 28(45):7248-55. PubMed ID: 20850534 [TBL] [Abstract][Full Text] [Related]
6. [Pharmacovigilance: a case of phantom ships and Russian roulette]. Stricker BH Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668 [TBL] [Abstract][Full Text] [Related]
7. European commission consultation on pharmacovigilance. Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839 [No Abstract] [Full Text] [Related]
8. Pharmacovigilance in clinical dentistry: overlooked or axiomatic? Carnelio S; Khan SA; Rodrigues G Gen Dent; 2011; 59(1):24-8; quiz 29-30, 80. PubMed ID: 21613036 [TBL] [Abstract][Full Text] [Related]
9. Reporting adverse effects: a practice to be encouraged. Prescrire Int; 2013 Mar; 22(136):83. PubMed ID: 23593701 [No Abstract] [Full Text] [Related]
10. International monitoring for adverse drug reactions of long latency. Fletcher AP; Griffin JP Adverse Drug React Toxicol Rev; 1991; 10(4):209-30. PubMed ID: 1793771 [No Abstract] [Full Text] [Related]
13. An underrecognized challenge in evaluating postmarketing drug safety. Roden DM Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350 [No Abstract] [Full Text] [Related]
14. Decision support methods for the detection of adverse events in post-marketing data. Hauben M; Bate A Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799 [TBL] [Abstract][Full Text] [Related]
15. [Organization and results of drug vigilance in France]. Bégaud B; Chaslerie A; Haramburu F Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001 [TBL] [Abstract][Full Text] [Related]
16. Safety in numbers--monitoring risk in approved drugs. Okie S N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493 [No Abstract] [Full Text] [Related]
18. The effect of backgrounds in safety analysis: the impact of comparison cases on what you see. Gogolak VV Pharmacoepidemiol Drug Saf; 2003; 12(3):249-52. PubMed ID: 12733479 [No Abstract] [Full Text] [Related]
19. Scientific challenges in postmarketing surveillance of ocular adverse drug reactions. Fraunfelder FW; Fraunfelder FT Am J Ophthalmol; 2007 Jan; 143(1):145-149. PubMed ID: 17188050 [TBL] [Abstract][Full Text] [Related]